Drug Trial Radar · NCT03974113
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jan 28, 2020
Primary completion
Aug 4, 2026
Study completion Aug 4, 2026
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 1 year, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: \- To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to \<12 years of age) with severe hemophilia A or B Secondary Objectives: * To characterize the safety and tolerability * To determine fitusiran plasma concentrations at selected time points
Conditions
- Hemophilia
Interventions
FitusiranDrug
Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma antithrombin (AT) activity levelsTime frame: Day 1 to the AT analysis time point at the optimal therapeutic dose (approximately 256 weeks)
Locations
16 sites in 6 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles Site Number : 8400002
Los Angeles, California
Hackensack University Medical Center- Site Number : 8400008
Hackensack, New Jersey
University Hospitals of Cleveland- Site Number : 8400007
Cleveland, Ohio
Penn State Milton S. Hershey Medical Center- Site Number : 8400006
Hershey, Pennsylvania
Investigational Site Number : 1240001
Hamilton, Ontario, Canada
Investigational Site Number : 1240002
Ottawa, Ontario, Canada
Investigational Site Number : 3560006
Bangalore, India
Investigational Site Number : 3560002
Mumbai, India
Investigational Site Number : 3560001
Pune-411011, India
Investigational Site Number : 3560004
Vellore, India
Investigational Site Number : 3800002
Florence, Italy
Investigational Site Number : 3800001
Milan, Italy
Investigational Site Number : 7240002
Madrid, Madrid, Comunidad de, Spain
Investigational Site Number : 7920001
Adana, Turkey (Türkiye)
Investigational Site Number : 7920002
Istanbul, Turkey (Türkiye)
Investigational Site Number : 7920003
Izmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.